Reuters logo
Israel's BiomX raises $24 mln in private funding round
May 15, 2017 / 12:09 PM / 7 months ago

Israel's BiomX raises $24 mln in private funding round

JERUSALEM, May 15 (Reuters) - BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures.

Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors also participated, the Israel-based company said.

The funds will be used to advance the firm’s therapeutic pipeline towards clinical stages.

BiomX develops treatments to alleviate diseases stemming from an imbalance in the microbiome - the bacteria in the human body. Its pipeline consists of products for the treatment of acne, inflammatory bowel disease and cancer. (Reporting by Steven Scheer)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below